New Data on Phase 1 Proposed Biosimilar Gan Lee Insulins Asp...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BEIJING and BRIDGEWATER, NJ. July 2, 2021 /PRNewswire-AsiaNet/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), announced positive Phase 1 clinical trial results at the 81st Scientific Sessions of the American Diabetes Association (ADA), June 25th - 29th. The ...
Authors: LATEST ASIANET NEWS RELEASES